Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 1, 2011, Pages

  Zarjou, Abolfazl ^a   Kim, Junghyun ^a   Traylor, Amie M ^a   Sanders, Paul W ^a,c   Balla, József ^b   Agarwal, Anupam ^a,c   Curtis, Lisa M ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Multiple organ failure; Nephrotoxicity; Renoprotective effects

Indexed keywords

CISPLATIN; HEME OXYGENASE 1; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL HYPOXIA; CELL ISOLATION; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 78651318022     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00594.2010     Document Type: Article

References (47)

1. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60: 79-127, 2008. (Pubitemid 351439218)
2. Agarwal A, Nick HS. Renal response to tissue injury: lessons from heme oxygenase-1 gene ablation and expression. J Am Soc Nephrol 11: 965-973, 2000. (Pubitemid 30241733)
3. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci 1176: 101-117, 2009.
4. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341-347, 2007.
5. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
6. Cerda J, Lameire N, Eggers P, Pannu N, Uchino S, Wang H, Bagga A, Levin A. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 3: 881-886, 2008.
7. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53: 961-973, 2009.
8. Crowley ST, Peixoto AJ. Acute kidney injury in the intensive care unit. Clin Chest Med 30: 29-43, vii-viii, 2009.
9. Cruz DN, Bagshaw SM, Ronco C, Ricci Z. Acute kidney injury: classification and staging. Contrib Nephrol 164: 24-32, 2010.
10. Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi S, Lach R, Hock TD, Chen B, Hill-Kapturczak N, Siegal GP, Dulak J, Jozkowicz A, Grant MB, Agarwal A. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 204: 605-618, 2007.
11. Devine SM. Mesenchymal stem cells: will they have a role in the clinic? J Cell Biochem Suppl 38: 73-79, 2002.
12. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 37: 1097-1104, 2004.
13. Goldberg R, Dennen P. Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis 15: 297-307, 2008.
14. Han W, Yu Y, Liu XY. Local signals in stem cell-based bone marrow regeneration. Cell Res 16: 189-195, 2006.
15. Hegyi B, Sagi B, Kovacs J, Kiss J, Urban VS, Meszaros G, Monostori E, Uher F. Identical, similar or different? Learning about immunomodulatory function of mesenchymal stem cells isolated from various mouse tissues: bone marrow, spleen, thymus and aorta wall. Int Immunol 22: 551-559, 2010.
16. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 14: 1035-1041, 2004.
17. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-8937, 2002.
18. Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 11: 56-62, 2009.
19. Jiang YB, Chen LJ, Tang YL, Ma GS, Qi CM, Zhu Q, Zhang XL, Yao YY, Liu NF, Shen CX. Effects of autologous mesenchymal stem cells transfected with heme oxygenase-1 gene transplantation on ischemic Swine hearts. Zhonghua Xin Xue Guan Bing Za Zhi 37: 692-695, 2009.
20. Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2: 364-377, 2006.
21. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262: 509-525, 2007. (Pubitemid 47620502)
22. Mishra PK. Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation? J Cardiovasc Med (Hagerstown) 9: 122-128, 2008.
23. Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26: 2075-2082, 2008.
24. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int 70: 432-443, 2006.
25. Oeyen S, Vandijck D, Benoit D, Decruyenaere J, Annemans L, Hoste E. Long-term outcome after acute kidney injury in critically-ill patients. Acta Clin Belg Suppl 2: 337-340, 2007.
26. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 136: 42-60, 1988.
27. Ozaki KS, Marques GM, Nogueira E, Feitoza RQ, Cenedeze MA, Franco MF, Mazzali M, Soares MP, Pacheco-Silva A, Camara NO. Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism. Clin Transplant 22: 609-616, 2008.
28. Pistoia V, Raffaghello L. Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev Clin Immunol 6: 211-218, 2010.
29. Pountos I, Corscadden D, Emery P, Giannoudis PV. Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. Injury 38, Suppl 4: S23-S33, 2007.
30. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 100, Suppl 1: 11917-11923, 2003.
31. Sheu CC, Zhai R, Wang Z, Gong MN, Tejera P, Chen F, Su L, Thompson BT, Christiani DC. Heme oxygenase-1 microsatellite polymorphism and haplotypes are associated with the development of acute respiratory distress syndrome. Intensive Care Med 35: 1343-1351, 2009.
32. Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 4: 102-106, 2009.
33. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 71: 266-271, 2007.
34. Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 18: 475-485, 2009.
35. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31-F42, 2005. (Pubitemid 40863570)
36. Togel F, Isaac J, Hu Z, Weiss K, Westenfelder C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int 67: 1772-1784, 2005.
37. Togel F, Zhang P, Hu Z, Westenfelder C. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J Cell Mol Med 13: 2109-2114, 2009.
38. Togel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 6: 179-183, 2010.
39. Tomanek RJ, Lund DD, Yue X. Hypoxic induction of myocardial vascularization during development. Adv Exp Med Biol 543: 139-149, 2003.
40. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 18: 414-420, 2007.
41. Tsubokawa T, Yagi K, Nakanishi C, Zuka M, Nohara A, Ino H, Fujino N, Konno T, Kawashiri MA, Ishibashi-Ueda H, Nagaya N, Yamagishi M. Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am J Physiol Heart Circ Physiol 298: H1320-H1329, 2010.
42. Vandijck DM, Oeyen S, Decruyenaere JM, Annemans L, Hoste EA. Acute kidney injury, length of stay, and costs in patients hospitalized in the intensive care unit. Acta Clin Belg Suppl 2: 341-345, 2007.
43. Waikar SS, Liu KD, Chertow GM. The incidence and prognostic significance of acute kidney injury. Curr Opin Nephrol Hypertens 16: 227-236, 2007.
44. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ, Kondo A, Kadota T, Baba T, Tayra JT, Kikuchi Y, Miyoshi Y, Date I. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 11: 52, 2010.
45. Weil BR, Markel TA, Herrmann JL, Abarbanell AM, Meldrum DR. Mesenchymal stem cells enhance the viability and proliferation of human fetal intestinal epithelial cells following hypoxic injury via paracrine mechanisms. Surgery 146: 190-197, 2009.
46. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103: 129-135, 1999.
47. Zeng B, Ren X, Lin G, Zhu C, Chen H, Yin J, Jiang H, Yang B, Ding D. Paracrine action of HO-1-modified mesenchymal stem cells mediates cardiac protection and functional improvement. Cell Biol Int 32: 1256-1264, 2008.